# Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

> **NCT01505868** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 170 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Lymphadenopathy
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Prostate Carcinoma Metastatic in the Bone
- Prostate Small Cell Carcinoma

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01505868
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-11
- **Primary completion:** 2019-12-09
- **Final completion:** 2019-12-09
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2021-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01505868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01505868, "Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01505868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*